Article
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies
13 Aug 2019
Abstract excerpt
Abstract Background Incorporation of next-generation sequencing (NGS) technology into clinical utility in targeted and immunotherapies requires stringent validation, including the assessment of tumor mutational burden (TMB) and microsatellite instability (MSI) status by NGS as important biomarkers for response to immune checkpoint inhibitors. Materials and Methods We designed an NGS assay, Cancer Sequencing YS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
